<?xml version="1.0" encoding="UTF-8"?>
<ref id="B179-biomedicines-08-00109">
 <label>179.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Li</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Xie</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Cai</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Wen</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Guan</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Mo</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Peng</surname>
    <given-names>P.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)</article-title>
  <source>medRxiv</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1101/2020.03.19.20038984</pub-id>
 </element-citation>
</ref>
